GENB

GENB remains in a broader bullish context with price holding above its medium- and long-term moving averages. Recent price has pulled back into the converging 9-, 20-, and 50-day EMAs, presenting a potential entry zone upon clear acceptance. RSI is neutral, and no exhaustion signals are visible, but a decisive break below the 50-day would negate the bullish setup. Patience is advised until pullback into the EMAs is absorbed, confirming support before committing.

• ↑Cash position of $457.4M supports runway into H1 2028.
• ↑GB-0895 Phase 3 asthma trial holds FDA Fast Track designation.
• ↓Q2 collaboration revenue fell to $6.3M from $10.1M YOY.